Botulinum toxin in ophthalmology.
Alan B. Scott selected, researched and developed Type A Botulinum toxin for clinical use in ophthalmology. This unique drug has proved invaluable for treatment of a number of conditions which are difficult to treat in ophthalmology and in a variety of other disciplines. The indications, methods and problems of its use are described and the results of treatment of 133 patients are discussed. Up to December 1986 over 13,000 patients have been treated in a multicentre international trial without significant complications.
Dunlop
D
D
Pittar
G
G
Dunlop
C
C
D000368:Aged; D000369:Aged, 80 and over; D001764:Blepharospasm / Q000188:drug therapy* / Q000503:physiopathology; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005141:Eyelid Diseases / Q000188:drug therapy*; D005152:Facial Muscles / Q000503:physiopathology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009045:Motor Endplate / Q000503:physiopathology; D009801:Oculomotor Muscles / Q000294:innervation; D013035:Spasm / Q000188:drug therapy; D013285:Strabismus / Q000188:drug therapy* / Q000503:physiopathology
D001905:Botulinum Toxins